
Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update
Description
Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update
Summary
GlobalData's Medical Devices sector report, “Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Next Generation Sequencing (NGS) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based. NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Next Generation Sequencing (NGS) Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Next Generation Sequencing (NGS) Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Next Generation Sequencing (NGS) Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
284 Pages
- About GlobalData
- Next Generation Sequencing (NGS) Tests Overview
- Next Generation Sequencing (NGS) Tests - Pipeline Products by Stage of Development
- Next Generation Sequencing (NGS) Tests - Pipeline Products by Territory
- Next Generation Sequencing (NGS) Tests - Pipeline Products by Regulatory Path
- Next Generation Sequencing (NGS) Tests - Pipeline Products by Estimated Approval Date
- Next Generation Sequencing (NGS) Tests - Ongoing Clinical Trials
- Next Generation Sequencing (NGS) Tests Companies - Pipeline Products by Stage of Development
- Next Generation Sequencing (NGS) Tests - Companies Pipeline Products by Stage of Development
- 4bases SA Company Overview
- AccuraGen Inc Company Overview
- ACT Genomics Co LTD Company Overview
- Adaptive Biotechnologies Corp Company Overview
- Almac Diagnostic Services Ltd Company Overview
- Amoy Diagnostics Co Ltd Company Overview
- AnchorDx Medical Co Ltd Company Overview
- ArcherDx Inc Company Overview
- Berry Oncology Corp Company Overview
- BGI Genomics Co Ltd Company Overview
- Biocartis Group NV Company Overview
- Biodesix Inc Company Overview
- BioLink Company Overview
- bioTheranostics Inc Company Overview
- Boston University Company Overview
- Buhlmann Laboratories AG Company Overview
- Burning Rock Biotech Ltd Company Overview
- Cardiff Oncology Inc Company Overview
- Cerba HealthCare SAS Company Overview
- DCGen Co Ltd Company Overview
- Eiken Chemical Co Ltd Company Overview
- Epic Sciences Inc Company Overview
- Epigenomics AG Company Overview
- First Genetics JCS Company Overview
- Flomics Biotech Company Overview
- Foundation Medicine Inc Company Overview
- Freenome Inc Company Overview
- Gencurix Inc Company Overview
- GeneCast Biotechnology Co Ltd Company Overview
- Geneseeq Technology Inc Company Overview
- Genetron Health (Beijing) Co Ltd Company Overview
- Genomic Health Inc Company Overview
- GigaGen Inc Company Overview
- HaploX Biotechnology Co Ltd Company Overview
- Haystack Oncology Inc Company Overview
- HTG Molecular Diagnostics Inc Company Overview
- Illumina Inc Company Overview
- Immunovia AB Company Overview
- Inivata Ltd Company Overview
- Insight Genetics Inc Company Overview
- InVivoScribe Technologies Inc Company Overview
- IvyGene Diagnostics Company Overview
- Laboratory Corp of America Holdings Company Overview
- Leto Laboratories Co Ltd Company Overview
- Lucence Diagnostics Pte Ltd Company Overview
- MedySapiens Inc Company Overview
- Mega Genomics Ltd Company Overview
- MolecularMD Corp Company Overview
- NGeneBio Co Ltd Company Overview
- Novigenix SA Company Overview
- Novomics Co Ltd Company Overview
- NuGEN Technologies Inc Company Overview
- NuProbe Inc Company Overview
- Oncodiag Company Overview
- OncoDNA SA Company Overview
- OncoSpire Genomics Company Overview
- OncXerna Therapeutics Inc Company Overview
- OrigiMed Inc Company Overview
- Otsuka Medical Devices Co Ltd Company Overview
- Pasteur Institute Company Overview
- Personal Genome Diagnostics Inc Company Overview
- Pillar Biosciences Inc Company Overview
- Predicine Inc Company Overview
- Predictive Biosciences Inc (Inactive) Company Overview
- Qiagen NV Company Overview
- Quantgene Inc Company Overview
- Queen's University Company Overview
- RealSeq Biosciences Inc Company Overview
- Rhodx Inc Company Overview
- Roche Diagnostics International Ltd Company Overview
- SeqOne SAS Company Overview
- Silicon Biosystems S.p.A. Company Overview
- Sophia Genetics SA Company Overview
- Spectrum Solutions LLC Company Overview
- Sysmex Corp Company Overview
- Sysmex Inostics GmbH Company Overview
- Tempus Health Inc Company Overview
- Thermo Fisher Scientific Inc Company Overview
- Trivitron Healthcare Pvt Ltd Company Overview
- TwinStrand Biosciences Inc Company Overview
- University of Chicago Company Overview
- University of Michigan Rogel Cancer Center Company Overview
- University of Texas Health Science Center at Houston Company Overview
- Vyant Bio Inc Company Overview
- Dec 09, 2023: Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ in Patients with Blood Cancers at the 65th ASH Annual Meeting
- Dec 05, 2023: Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of Clonoseq MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
- Dec 05, 2023: NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
- Dec 01, 2023: Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium
- Nov 20, 2023: U.S. FDA Approves FoundationOne CDx as a Companion Diagnostic for AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) to Identify Patients with HRPositive, HER2-Negative Advanced Breast Cancer
- Nov 20, 2023: Roswell Park Launches Advanced, High-Speed Blood Cancer Test
- Nov 15, 2023: Tempus Announces Medicare Coverage for Tempus xT Across Solid Tumor and Hematologic Malignancies
- Nov 14, 2023: Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
- Nov 06, 2023: Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
- Oct 26, 2023: Foundation Medicine Announces Participation in National Cancer Institute's ComboMATCH Initiative to Connect Patients with New Anti-Cancer Drug Combinations
- Oct 21, 2023: Foundation Medicine Expands Partnership With Sequanta to Provide Both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings
- Oct 19, 2023: Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting
- Oct 18, 2023: New Data Highlights Clinical Utility and Performance of Castle Biosciences' Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference
- Oct 17, 2023: Predicine Announces Six Studies Showcasing Mrd and Liquid Biopsy Innovations at ESMO 2023
- Oct 15, 2023: Burning Rock Received Breakthrough Device Designation from China's NMPA for its Multi-Cancer Early Detection Test
- Oct 13, 2023: Geneseeq Receives Chinese NMPA Approval for Lung Cancer Tumor Mutational Burden NGS Test Kit
- Oct 12, 2023: FDA Approves FoundationOneCDx and FoundationOnLiquid CDx as Companion Diagnostics for Pfizer's BRAFTOVI (encorafenib) in Combination With MEKTOVI (binimetinib) to Identify Patients with BRAF V600E Alterations in Metastatic NSCLC
- Oct 10, 2023: Karius Test Improves the Diagnosis and Management of Pneumonia in Patients Undergoing Treatment for Blood Cancer
- Oct 09, 2023: U.S. Food and Drug Administration (FDA) Approves FoundationOne CDx as a Companion Diagnostic for Lilly's Retevmo (selpercatinib) for Certain Patients with Solid Tumors
- Oct 03, 2023: Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of Decisiondx-Scc in Patients With Cutaneous Squamous Cell Carcinoma Eligible for
- Sep 28, 2023: New Neoadjuvant Trial Confirms the Predictive Utility of Mammaprint + Blueprint
- Sep 20, 2023: Predicine Announces New Study Published in the New England Journal of Medicine Demonstrating Clinical Utility of Its Mrd Liquid Biopsy Assay in Supporting Genentech's Phase 1 Clinical Trial of Divarasib
- Sep 19, 2023: Pillar Biosciences Launches oncoReveal Core LBx, an NGS Kit to Enable Localized Liquid Biopsy Testing
- Sep 19, 2023: Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
- Sep 07, 2023: Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer
- Aug 22, 2023: New Study Shows UroAmp Can Detect Bladder Cancer Not Found by Cystoscopy or Urine Cytology
- Aug 22, 2023: Myriad Genetics And Onsite Women's Health Partner To Help More Women Understand Breast Cancer Risk
- Aug 22, 2023: Geneseeq Gains CE Marks For NGS-based Test Kits For Solid Tumors And Hematological Cancer
- Aug 21, 2023: Scale Biosciences And Basepair To Democratize Single Cell Sequencing Data Analysis
- Aug 16, 2023: 4BASES Announces the Readiness of a CFTR Mutations Detection Solution
- Aug 14, 2023: U.S. Food and Drug Administration (FDA) Approves FoundationOne CDx as a Companion Diagnostic for Janssen's AKEEGA (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
- Aug 02, 2023: Karius Test, a Liquid Biopsy for Infectious Diseases, Incorporated into Diagnostics Recommendation in the 2023 Duke-ISCVID Criteria for Infective Endocarditis
- Jul 27, 2023: NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
- Jul 24, 2023: Myriad Genetics Announces Inclusion of Breast Density to MyRisk with RiskScore Breast Cancer Risk Assessment
- Jul 12, 2023: Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study
- Jul 04, 2023: China's NMPA approves LAMH's liver cancer detection test
- Jun 30, 2023: Novigenix Reports Interim European Validation Data on Its New NGS-Based Whole Blood RNA Signature for Detection of Advanced Colorectal Adenomas
- Jun 15, 2023: Neogenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
- Jun 12, 2023: FDA approves FoundationOne Liquid CDx as companion diagnostic for Braftovi
- Jun 12, 2023: Castle Biosciences Presents New Data Demonstrating the Ability of Decisiondx-SCC to Identify Tumors Likely to Metastasize in Patients With Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging
- Jun 08, 2023: Burning Rock's Precision Oncology Diagnostics Product Supports Advancement in Late- Stage Breast Cancer Treatment, With Results Published in the New England Journal of Medicine
- Jun 08, 2023: Imbdx Expands Targeted Therapies Agreement Following Successful Evaluation of Blood-Based Genomic Profiling Assay in Prostate Cancer
- Jun 08, 2023: Published in the New England Journal of Medicine
- Jun 05, 2023: Framework incorporating DecisionDx-SCC test results into clinical decision-making for patients with high-risk cutaneous squamous cell carcinoma published in Clinical, Cosmetic and Investigational Dermatology
- Jun 05, 2023: NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
- Jun 02, 2023: Adaptive Biotechnologies highlights new data at ASCO 2023 and EHA 2023 underscoring the clonoSEQ assay's Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
- Jun 01, 2023: Labcorp introduces new liquid biopsy test
- May 31, 2023: Agendia studies reveal the influence of race on a tumor's biology, reinforcing its commitment to advancing research of racial disparities in breast cancer
- May 30, 2023: NeoGenomics to showcase the transformational impact of RaDaR assay for molecular residual disease and recurrence monitoring at ASCO
- May 26, 2023: Foundation Medicine and its collaborators announce acceptance of 21 Abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- May 25, 2023: Digi7 launches Geneyx AI-based solution to analyse next-generation sequencing data at Mediclinic
- May 23, 2023: Tempus Labs receives CLIA approval for xT CDx Test
- May 11, 2023: Tempus Labs obtains Pre-Market Approval (PMA) for xT CDx Test
- May 02, 2023: Tempus receives FDA approval for NGS-based test xT CDx
- Apr 28, 2023: Predicine to introduce PredicineALERT MRD Assay and present two ctDNA studies in genitourinary cancers at AUA 2023 Annual Meeting
- Apr 25, 2023: Strata Oncology announces launch and medicare coverage for Strata Select, a first-ofits- kind immunotherapy test
- Apr 25, 2023: New Studies on Convergent Genomics' Urine Test for Bladder Cancer to be Presented at 2023 American Urological Association (AUA) Annual Meeting
- Apr 19, 2023: Epic Sciences announces medicare coverage for breast-cancer focused ctDNA Gene Panel
- Apr 18, 2023: Myriad Genetics and Intermountain Precision Genomics now offer solid tumor testing in all 50 States with latest NY State Certification
- Apr 17, 2023: Thermo Fisher Scientific Announces Oncomine Clinical Research Grant Awardees and Opens Spring 2023 Submissions
- Apr 13, 2023: Myriad Genetics and SimonMed team up for genetic cancer risk programme
- Apr 06, 2023: NeoGenomics to share nine abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
- Apr 03, 2023: Tempus announces second sequencing collaboration with Lilly to expand patient access to genomic testing
- Mar 18, 2023: Late-Breaking data presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx-SCC in predicting metastatic risk over traditional staging systems in independent, multi-center cohort study
- Mar 16, 2023: NeoGenomics announces commercial availability of the RaDaR Molecular Residual Disease Test
- Mar 14, 2023: The Future Of Cancer Care: Next-Generation Sequencing Available at Cooperman Barnabas Medical Center
- Mar 10, 2023: Castle Biosciences to highlight clinical value of its skin cancer tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
- Mar 06, 2023: Freenome presents a subject population analysis of a clinical study using a multiomics blood test for the early detection of colorectal cancer
- Mar 02, 2023: Point32Health and Foundation Medicine expand access to comprehensive genomic profiling for members with advanced cancer
- Mar 02, 2023: Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
- Feb 22, 2023: SeqOne's new clinically validated HRD test reduces number of inconclusive results to improve the prescription of targeted treatments for ovarian cancer patients
- Feb 21, 2023: iGene Laboratory announces launch of whole exome sequencing service
- Feb 09, 2023: UnitedHealthcare provides commercial coverage for FoundationOne CDx and FoundationOne Liquid CDx in multiple companion diagnostic indications
- Feb 07, 2023: Exact Sciences launches OncoExTra cancer therapy selection test in the U.S.
- Feb 06, 2023: RaDaR(R) assay demonstrates clinical potential for helping Oncologists determine whether or not muscle-invasive bladder cancer patients undergo radical surgery
- Jan 24, 2023: ACT Genomics receives CLIA approval for ACTOnco IVD Test
- Jan 24, 2023: ACT Genomics receives CLIA approval for ACTOnco Test
- Jan 10, 2023: Prenetics owned ACT Genomics receives FDA clearance for ACTOnco, the first Asiabased company to receive clearance for a comprehensive genomic profiling test for all solid tumors
- Jan 03, 2023: ACT Genomics receives 510(k) clearance for ACTOnco IVD Test
- Jan 03, 2023: ACT Genomics receives 510(k) clearance for ACTOnco Test
- Dec 21, 2022: Foundation Medicine receives FDA approval for FoundationOneLiquid CDx as a companion diagnostic for a certain group of tyrosine kinase inhibitors for treatment of non-small cell lung cancer patients
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.